Svetlovska Daniela, Miskovska Viera, Cholujova Dana, Gronesova Paulina, Cingelova Silvia, Chovanec Michal, Sycova-Mila Zuzana, Obertova Jana, Palacka Patrik, Rajec Jan, Kalavska Katarina, Usakova Vanda, Luha Jan, Ondrus Dalibor, Spanik Stanislav, Mardiak Jozef, Mego Michal
Translational Research Unit, Comenius University, Faculty of Medicine, Bratislava, Slovakia; Department of Clinical Trials, National Cancer Institute, Bratislava, Slovakia.
1st Department of Oncology, Comenius University, Faculty of Medicine and St. Elisabeth Cancer Institute, Bratislava, Slovakia.
Clin Genitourin Cancer. 2017 Jun;15(3):411-416.e2. doi: 10.1016/j.clgc.2017.01.027. Epub 2017 Feb 8.
Cytokines are the communicators of immune system and are involved in all immune responses. The aim of this study was to assess the correlation among plasma cytokines, patient and tumor characteristics, and clinical outcome in chemonaive testicular germ-cell tumor (TGCT) patients.
This study included 92 metastatic chemotherapy-naive TGCT patients treated with platinum-based chemotherapy from July 2010 to March 2014. Plasma was isolated before first administration of chemotherapy, and the concentration of 51 plasma cytokines were analyzed using multiplex bead arrays.
At a median follow-up of 33.2 months (range, 0.1-54.8 months), 10.9% of patients experienced disease progression, and 7.6% died. Several cytokines were associated with different baseline clinicopathologic features. Elevated plasma levels of interferon (IFN)-α2, interleukin (IL)-2Rα, IL-16, hepatocyte growth factor (HGF), and monocyte chemotactic protein (MCP)-3 were significantly associated with worse progression-free survival and overall survival (OS). Moreover, elevated levels of stem-cell growth factor (SCGF)-β were also associated with worse OS. Patients with elevated levels of all 6 cytokines experienced significantly worse outcomes compared to patients who had fewer than 6 cytokines elevated (hazard ratio = 12.06; 95% confidence interval, 7.39-19.49; P = .002 for progression-free survival, and hazard ratio = 39.65; 95% confidence interval, 25.03-62.18; P < .00001 for OS, respectively). Results were independent of International Germ Cell Cancer Collaborative Group criteria.
We found a correlation among progression free-survival, OS, and circulating cytokines in TGCT. This suggests the existence an association between plasma cytokines and baseline clinicopathologic features in TGCT. Plasma cytokines could be used for identification of high-risk patients who are candidates for new therapeutic approaches.
细胞因子是免疫系统的通讯分子，参与所有免疫反应。本研究旨在评估初治睾丸生殖细胞肿瘤（TGCT）患者血浆细胞因子、患者及肿瘤特征与临床结局之间的相关性。
本研究纳入了2010年7月至2014年3月期间接受铂类化疗的92例转移性初治TGCT患者。在首次化疗前采集血浆，使用多重微珠阵列分析51种血浆细胞因子的浓度。
中位随访33.2个月（范围0.1 - 54.8个月），10.9%的患者出现疾病进展，7.6%的患者死亡。几种细胞因子与不同的基线临床病理特征相关。血浆干扰素（IFN）-α2、白细胞介素（IL）-2Rα、IL-16、肝细胞生长因子（HGF）和单核细胞趋化蛋白（MCP）-3水平升高与无进展生存期和总生存期（OS）较差显著相关。此外，干细胞生长因子（SCGF）-β水平升高也与较差的OS相关。与细胞因子升高少于6种的患者相比，所有6种细胞因子水平均升高的患者结局明显更差（无进展生存期的风险比 = 12.06；95%置信区间，7.39 - 19.49；P = 0.002，OS的风险比 = 39.65；95%置信区间，25.03 - 62.18；P < 0.00001）。结果与国际生殖细胞癌协作组标准无关。
我们发现TGCT患者的无进展生存期、OS与循环细胞因子之间存在相关性。这表明TGCT患者血浆细胞因子与基线临床病理特征之间存在关联。血浆细胞因子可用于识别适合新治疗方法的高危患者。
